Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro

Journal of Neuroimmunology

Volumn 86, Issue 2, 1998, Pages 155-162

  Malik, O ^a   Compston, D A S ^a   Scolding, N J ^a  

^a NONE

Author keywords

Cytokines; Growth factors; Multiple sclerosis; Reactive astrocyte

Indexed keywords

BETA INTERFERON;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL PROLIFERATION; MITOGENESIS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES; ANTIBODY SPECIFICITY; ASTROCYTES; BINDING, COMPETITIVE; CELL DIVISION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERFERON-BETA; MITOGENS; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032525977     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00049-6     Document Type: Article

References (46)

1. Arnason B.G.W. Interferon beta in multiple sclerosis. Clin. Immunol. Immunopathol. 81(1):1996;1-11.
2. Barna B.P., Estes M.L., Jacobs B., Hudson S., Ransohoff R.M. Human astrocytes proliferate in response to tumour necrosis factor alpha. J. Neuroimmunol. 30:1990;239-243.
3. Brück W., Schmied M., Suchanek G., Brück Y., Breitschopf H., Poser S., Piddelsden S., Lassmann H. Oligodendrocytes in the early course of multiple sclerosis. Ann. Neurol. 35:1994;65-73.
4. Chalk J.B., McCombe P.A., Pender M.P. Restoration of conduction in the spinal roots correlates with clinical recovery form experimental allergic encephalomyelitis. Muscle Nerve. 18(10):1995;1093-1100.
5. Cook A.W., Carter W.A., Nidzgorski F., Akhtar L. Human brain tumour derived cell lines - growth rate reduced by human fibroblast interferon. Science. 219(4586):1983;881-883.
6. Dawson, J.W., 1916. The histology of disseminated sclerosis. Edinb. Med. J., 17, 229-241, 311-344, 377-410.
7. Interferon Beta-1b Study Group Interferon Beta-1b in the treatment of multiple sclerosis - final outcome of the randomised control trial. Neurology. 45(7):1995;1277-1285.
8. Garrison J.I., Berens M.E., Shapiro J.R., Treasurywala S., Floyd-Smith G. Interferon beta inhibits proliferation and progression through S-phase of the cell cycle in 5 glioma cell lines. J. Neuro-Oncol. 30(3):1996;213-223.
9. Genka S., Shitara M., Tsujita Y., Kosugi Y., Takakura K. Effect of IFN-β on the cell cycle of human glioma cell line U-251 MG - flow cytometric 2-D (BrDU DNA0 analysis). J. Neuro-Oncol. 6(4):1988;299-307.
10. Gross R.G., Mehler M.F., Mabie P.C., Zang Z., Santschi L., Kessler J.A. Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron. 17:1996;595-606.
11. Hall G.L., Wing M.G., Scolding N.J., Compston D.A.S. Beta interferon regulates the immunomodulatory activity of rodent microglia. J. Neuroimmunol. 72(1):1996;11-19.
12. Hatten M.E., Liem R.K.H., Mason C.A. Astroglia in CNS injury. Glia. 4:1991;233-243.
13. Hartung H.K., Keisier B.C. Targets for the therapeutic action of interferon beta in multiple sclerosis. Ann. Neurol. 40(6):1996;825-826.
14. Hohlfield R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain. 120:1995;865-916.
15. Hoke A., Silver J. Heterogeneity among astrocytes in reactive gliosis. Pers. Dev. Neurobiol. 2(3):1994;269-274.
16. Hunter K.E., Sporn M.B., Davies A.M. Transforming growth factor-β's inhibit mitogen stimulated proliferation of astrocytes. Glia. 7:1993;203-211.
17. Ihle J.N. STATs: signal transducers activators of transcription. Cell. 84:1996;331-334.
18. and the MS Study Group, Jacobs L.D. Interferon Beta-1α for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39(3):1996;285-294.
19. Lee S.-C., Dickson D.W., Brosnan C.F. Interleukin-1β, nitric oxide and reactive astrocytes. Brain, Behav., Immunol. 9(4):1995;345-354.
20. Lindholm D., Castren E., Kiefer R., Zafra F., Thoenen H. Transforming growth factor-β in the rat brain: increase after injury and inhibition of astrocyte proliferation. J. Cell Biol. 117(2):1992;395-400.
21. Lindsay, R.M., 1986. Reactive gliosis. In: Federoff, S., Vernadakis, A. (Eds.), Astrocytes. Academic Press, Orlando, FL, pp. 231-262.
22. Logan A., Frautschy S.A., Gonzalez A.M., Sporn M.B., Baird A. Enhanced expression of transforming growth factor-β in the rat brain after a localised cerebral injury. Brain Res. 587:1992;216-225.
23. Logan A., Berry M., Gonzalez A.M., Frautschy S.A., Sporn M.B., Baird A. Effects of transforming growth factor β on scar production in the injured central nervous system of the rat. Eur. J. Neurosci. 6:1994;355-363.
24. McCarthy K.D., de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 85:1980;890-902.
25. Miller D.H., Barkhoff F., Nauta J.J.P. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in MS. Brain. 116(5):1993;1077-1094.
26. Miller R.H. Oligodendrocyte origins. Trends Neurosci. 19(3):1996;92-96.
27. Navikas V., Link H. Review: Cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 45:1996;322-333.
28. Prineas J.W., Kwon E.E., Goldenberg P.Z., Cho E.S., Sharer L.R. Interaction of astrocytes and newly formed oligodendrocytes in resolving multiple sclerosis lesions. Lab. Inves. 63:1990;624.
29. Prineas J.W., Barnard R.O., Kwon E.E., Sharer L.R., Cho E.-S. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol. 33(2):1993;137-145.
30. Raine C.S., Wu E. Multiple sclerosis: remyelination in acute lesions. J. Neuropathol. Exp. Neurol. 52:1993;199-204.
31. Rosen C.L., Bunge R.P., Ard M.D., Wood P.M. Type-1 astrocytes inhibit myelination by adult rat oligodendrocytes in vitro. J. Neurosci. 9:1989;3371-3379.
32. Sawcer S., Goodfellow P.N., Compston D.A.S. Genetic analysis of multiple sclerosis. Trends Genet. Sci. 13(6):1997;234-239.
33. Schwartz P.S., Wilson D.J. Preparation and characterisation of type-1 astrocytes cultured from adult rat cortex, cerebellum and striatum. Glia. 5:1992;75-80.
34. Scolding N.J., Zaijcek J., Wood N., Compston D.A.S. Pathogenesis of demyelinating disease. Prog. Neurobiol. 43:1994;143-173.
35. Selmaj K.W., Farooq M., Norton W.T., Raine C.S., Brosnan C.F. Proliferation of astrocytes in vitro in response to cytokines: a primary role for tumour necrosis factor alpha. J. Immunol. 144:1990;129-135.
36. Shao Y., McCarthy K.D. Plasticity of astrocytes. Glia. 11:1994;147-155.
37. Smith, R.A., 1987. Mapping the action of interferon on primate brain. In: Cantell, K., Schellekef, H. (Eds.), Biol. Interferon Syst. pp. 563-566.
38. St Pierre, B.A., Merrill, J.E., Dopp, J.M., 1996., Effects of cytokines on CNS cells. Glia. In: Ransohoff, R.M., Benveniste, C. (Eds.), Cytokines and the CNS, CRC Press, Boca Raton, FL, pp. 151-168.
39. Torre-Delbauffe D., Baghdassarian-Chalaye D., Gavaret J.M., Courtin F., Pomerance F., Pierre M. Effects of TGF-β on astroglial cells in culture. J. Neurochem. 54:1990;1056-1061.
40. Vergelli M., Mazzanti B., Ballerini C., Gran B., Amaducci L., Massacesi L. Transforming growth factor-β inhibits the proliferation of rat astrocytes induced by serum and growth factors. J. Neurosci. Res. 40:1995;127-133.
41. Vollmer T.L. Multiple sclerosis: new approaches to immuno-therapy. The Neuroscientist. 2(2):1996;127-136.
42. Wilkin G.P., Marriot D.R., Cholewinski A.J. Astrocyte heterogeneity. TINS. 13(2):1990;43-46.
43. Winter et al., 1995.
44. Yong V.W., Moumdjian R., Yong F.P., Ruijs T.C.G., Freedman M.S., Cashman N., Antel J.P. γ-Interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. Proc. Natl. Acad. Sci. USA. 88:1991;7016-7020.
45. Yong V.W., Tejada-Berges T., Goodyer C.G., Antel J.P., Yong F.P. Differential proliferative response of human and mouse astrocytes to interferon-γ Glia. 6:1992;269-280.
46. Yu R., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., Jove R. Enhanced DNA binding activity of a STAT-3 related protein in cells transformed by the src oncoprotein. Science. 269:1995;81-83.